Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS)

Show full item record



Vasarainen , H , Salman , J , Salminen , H , Valdagni , R , Pickles , T , Bangma , C , Roobol , M J & Rannikko , A 2015 , ' Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS) ' , World Journal of Urology , vol. 33 , no. 11 , pp. 1735-1740 .

Title: Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS)
Author: Vasarainen, Hanna; Salman, Jolanda; Salminen, Heidi; Valdagni, Riccardo; Pickles, Tom; Bangma, Chris; Roobol, Monique J.; Rannikko, Antti
Contributor organization: Clinicum
Department of Surgery
Urologian yksikkö
Date: 2015-11
Language: eng
Number of pages: 6
Belongs to series: World Journal of Urology
ISSN: 0724-4983
Abstract: To evaluate the utility of percentage of free serum PSA (%fPSA) as a predictor of adverse rebiopsy findings, treatment change and radical prostatectomy (RP) findings in a prospective active surveillance (AS) trial. Patients enrolled in the global PRIAS study with baseline %fPSA available were included. Putative baseline predictors (e.g. PSA, %fPSA) of adverse rebiopsy findings were explored using logistic regression analysis. Association of variables with treatment change and RP findings over time were evaluated with Cox regression analysis. Active treatment-free survival was assessed with a Kaplan-Meier method. Of 3701 patients recruited to PRIAS, 939 had %fPSA measured at study entry. Four hundred and thirty-eight of them had %fPSA available after 1 year. Median follow-up was 17.2 months. First rebiopsy results were available for 595 patients and of those, 144 (24.2 %) had adverse findings. A total of 283 (30.1 %) patients discontinued surveillance, of those 181 (64.0 %) due to protocol-based reasons. Although median %fPSA values were significantly lower in patients who changed treatment, according to the multivariate regression analysis, initial %fPSA value was not predictive for treatment change or adverse rebiopsy findings. However, the probability of discontinuing AS was significantly lower in patients with "favourable" initial %fPSA characteristics and %fPSA during follow-up (initial %fPSA a parts per thousand yen15 and positive %fPSA velocity) compared to those with "adverse" %fPSA characteristics (initial %fPSA <15 and negative %fPSA velocity). Diagnostic %fPSA provides no additional prognostic value when compared to other predictors already in use in AS protocols. However, %fPSA velocity during surveillance may aid in predicting the probability for future treatment change.
Subject: Prostate cancer
Active surveillance
Prostate-specific antigen
Free prostate-specific antigen
3122 Cancers
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
art_3A10.1007_2Fs00345_015_1542_3.pdf 460.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record